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Introduction 
CHAP f ERI 
Introduction 
Chirality is the key process of life. Louis Pasteur in 1848 described the concept of 
stereochemistry in organic molecules viz. tartaric acid which displayed the molecular 
asymmetry [1] by producing non-superimposible mirror image isomers. A molecule 
can exist in symmetric or asymmetric forms. The most common basis for asymmetric 
molecules is the centre of chirality -a stereogenic carbon center with four different 
ligands attached to it [2]. If the molecule and its mirror image are non-superimosible, 
the relationship between them is enantiomeric and two stereoisomers comprise an 
enantiomeric pair (Fig.l). Carbon is not the only atom that can act as asymmetric 
center, phosphorous, sulphur; nitrogen can also form chiral molecules [3]. The 
physical properties of enantiomeric pair (melting point, boiling point, refractive index, 
solubility) are generally identical but they differ in the way they interact with the 
plane of polarized light [3]. To distinguish the two forms, they are often designated 
right handed D-enantiomer or left handed L-enantiomer. L and D stands for laevo and 
dextro, respectively. Enantiomeric forms are found in many organic and inorganic 
substances and in essentially all molecules crucial for development of life especially 
proteins, which are responsible for the structure and chemical regulation of living cell, 
DNA, the molecule that carries genetic information, and amino acids. Many 
biochemical processes and phenomenon are stereospecific. The L- and D-enantiomers 
of amino acids have different tastes [4,5], enantiomers of some compounds have 
different odours [6,7] and many medicinal preparations have physiological properties 
different from those of their enantiomers [8-10]. 
Fig 1. Molecular asymmetry arising from the attachment of four different ligands to 
tetravalent carbon-carbon atom: enantiomeric pair 
Lehman and coworkers [11] have developed a system of nomenclature to describe the 
biological activity of two enantiomeric pairs [12]. Often only one stereoisomer of a 
racemate drug is able to affect the desired process, the patient ends up absorbing and 
metabolizing unnecessary quantities of other stereoisomers of a drug [13], like 
thalidoamide racemate used for morning sickness led to the tragedy in 1960 in 
Europe. The (S)-enantiomer of thalidoamide exhibited neurotoxic tetralogical 
(mutagenic) effects in which babies were bom deformed. Similarly, many of the 
gastric and cardiovascular diseases are treated with superior efficacy by one of the 
two racemates. Esomeperazole trade name Naxium, a S (-)enantiomer of omeperazole 
and anti-inflammatory drugs like S- Ibuprofen (Fig.2) were preferred than 
contemperory coimterparts [14]. 
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Fig 2. Enantiomeric forms of drugs 
Therefore, there is a direct correlation between drug stereochemistry and biological 
activity pertaining to the development of stereoisomeric drugs. The process of 
enantiomeric separation leads to the chiral molecules that are produced as single 
isomers [11]. 
There is growing demand for chiral ligands, in material chemistry as small quantities 
of chiral organic compounds can induce technologically important bulk properties in 
soft materials such as polymers, self-assembled monomers and liquid crystals. BINOL 
and BINAP are two of the most useful liquids developed to date (Fig.3). Derivatives 
of BINOL are employed in materials where they can induce helical structures in 
certain nematic liquids crystals particularly used in the propagation of chirality 
through non-covalent core-core interaction [15]. 
(a) 
Fig 3. (a) Binol (b) Binap 
(b) 
Chiral ligands and chiral auxiliaries with different molecular architectures [3] have 
been developed largely due to the application of these organic compounds in the 
synthesis of modem pharmaceutical drugs. In early 1990s, cis-l-(S)-amino-2-(R)-
indanol -a chiral auxiliary mediated the synthesis of (HIV)-1-protease inhibitor 
Crixivan (shown in Fig.4) [16]. 
NHa 
*^\ N ^ OH 
"'OH ' \ / N 
CONHtBu 
Cis-l-(S)-ainino-2 (R) indanol Crixivan 
Fig 4. Cis- l-(S)-amino-2(R) indanol (chiral auxiliary) mediated synthesis 
Among the various chiral compounds, chiral alcohols and amides represent a highly 
versatile and attractive group of chiral building blocks for the synthesis of various 
drugs and drug intermediates [17]. 
Linezolid, the oxazolidinone antibiotic is used to treat the patients with gram-positive 
infections, the most frequent cause of hospital infections. Amprenavir belongs to the 
family of antiretroviral drugs which is a protease inhibitor used for the treatment of 
HIV infections. Similarly, Lipitor (Atorvastatin) belong to a class of drugs named 
statins which reduce levels of total cholesterol and LDL (Fig.5). Chiral molecules in 
the pharmaceutical market show enormous growth and certainly access to these 
potential new drugs will depend highly as the development of asymmetric methods 
for the synthesis of chiral building blocks [13]. 
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Fig 5. Chiral Drugs (a) Linezolid (Zyvox) (b)Amprenavir (Agenerase) (c)Lipitor 
The asymmetric aza-Michael reaction of metal benzylamides to a,B-unsaturated 
amides derived from the chiral amino alcohols (S,S)-(+) pseudoephedrine has been 
studied in much detail [18]. These li-amino acid derivatives are extremely important 
compounds not only because of their ubiquitous occurrence as constituents of a 
plethora of biologically important natural and synthetic products but also they have 
shown to be very versatile intermediates in the synthesis of other nitrogen containing 
compounds. Further, it is a promising tactic to prepare peptide analogues with 
increased potency and enzymatic stability [19-22]. 
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Fig 6. Aza-Michael reaction of lithium dibezylamide or lithium benzylmethylamide to 
a, fi-unsaturated amides derived from chiral amino alcohol (S,S)-(+) 
pseudoephedrine 
The aza-Michael asymmetric reaction, where stereo controlled conjugate addition of 
nitrogen nucleophiles to a,6-unsaturated esters, amides, imides or related derivatives 
has been explored by many researchers for application of chiral compounds [23-27]. 
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Scheme 1. Two synthetic approaches to fh-amino acid derivatives 
Kraus et al [28] have recently designed, synthesized a thiazolamide conjugate that 
shows an improved pharmacokinetic profile compared to the parent thiazolamide drug 
for the treatment of cerebral diseases such as Alzheimers disease (Fig.7) 
(a) 
Fig 7. Structure ofthiazolamide (a) and its ascorbic acid conjugate (b) 
Many existing pharmaceuticals are rendered ineffective in the treatment of central 
nervous system (CNS) because of an inability to effectively deliver [29-32] and 
sustain their within the brain. Manipulating drug strategy has been investigated and it 
appears that lipophilic analogues [33-34]; Chemical drug delivery system CDDS [35-
37] which allows targeting of specific sites on predictable enzymatic activation. For 
example, linking a drug to dihydropyridine carrier creates a complex ionic pyridinium 
salt which can be traced inside the brain. 
The amide unit [38] is one of the most widely occurring functional groups and is an 
important feature in many biologically relevant natural and synthetic products. 
Numbers of methods are available for preparation of amides including ammonolysis 
of carboxylic acids and derivatives, thermal decomposition of ammonium salts of 
carboxylic acids, partial hydrolysis of cyanides, etc [39]. Recently some microwave 
assisted synthesis of amide in the presence of strong bases has also been reported [40-
42]. Metal salt catalyzed reactions are attracting considerable attention for example, 
reusable Zn dust has been employed for the conversion of aromatic carboxylic esters 
to secondary amides by treating primary amines in presence of N,N -
dimethylformamide with microwave heating / or conventional heating by stirring in 
an oil bath using THF as a solvent (shown in Fig.8) [39]. 
IJ MW, Zn/DMF or y 
A,Zn/THF 
Fig 8. Microwave assisted conversion of aromatic carboxylic esters to secondary 
amides. 
The naturally occurring amino acids have a common metal binding mode but the 
presence of different side chain residues results in significant differences in the 
thermodynamic stability and structural properties of amino acid complexes [43]. The 
inclusion of these amino acids into peptide bonds enhances the structural differences 
because of peptide provide almost iimumerable different sets of donor atoms and all 
of them are able to interact with significant conformational changes of biomolecules 
reflecting the indirect role of metallopeptide chemistry in biological systems. 
However, the amide group [44] is a weak acid [45, 46] and its metal ion coordination 
requires the presence of an anchoring donor group. The metal binding ability of 
peptides is influenced significantly by the presence of various effective side chain 
donor groups or atoms like imidazole N and mercapto S. 
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Seebach et al. [47] have recently reported methylthiomethylation and subsequent 
sulfoxi dation, pyrolysis of N-Boc-protected (i^-amino acid metyl esters of alanine, 
valine, leucine to give a-methyl esters. The stepwise coupling solution procedure 
yields novel fi-peptides (shown in scheme 2). 
Bu'O R OLi 
L i O ' ^ N - ' ' * " - ^ O M e 
Boc 
CH2 
MeSCH2CI/Nal Boc ^  ,X^ ^CO 
— —»^ N >r^ 
THF/DME 
-78 to -30°C 
22 h 
excess H202 
HgO/EtOH 
room temp., 15min 
C02Me -*- 80-90°C 
pyridine 
20-40h 
Me 
SMe 
Boc^ ,,J^,^^C02Me 
w X . 
"SOMe 
Scheme 2. Synthesis of methyl N-Boc-(S)-2-methylene-3-aminoalkanoates derived 
from Alanine, Valine and Leucine 
All coupling reactions reduce (l-oligopeptides in good yields and were readily purified 
by flash chromatography or by reverse phase HPLC. The NMR spectrum of these 
peptides showed well resolved signals for methylene hydrogens but not for the NH 
protons (8.17-8.34ppm). Every amino acid moiety was surprisingly stable and form 
strong intermolecular hydrogen bonding networks. 
Yu-fie-Song [48] has synthesized two peptides cytotoxic agent conjugates namely 
DMQ-MA-Lys(Cbz)-Arg-OMe, DMQ-MA-Lys(DMQ-MA)-Phe-Arg-OMe, DMQ-
MA-Lys(DMQ-MA)-Ile-Arg-OMe and DMQ-MA-Lys(DMQ-MA)-Val-Arg-OMe. 2, 
6-ciimethoxyhydroquionone-3-mercaptoacetic acid (DMQ-MA) is a natural product of 
fermented wheatgerm. DMQ-MA peptide congeners have displayed enhanced invitro 
activity compared to the parent compound. Many acceptors of amino acids, peptides 
or amylases exist on the surface of tumour cells, and these cells can absorb nutrients 
to propagate and proliferate. DMQ-MA peptide can access the tumour cells and 
exhibit their pharmacological effect. 
Multifunctional ligands introduced into the metal based medicinal agents limit the 
adverse effects with maximal curative potential and minimal side effects [49, 50]. 
Further, Piperazinyl benzimidazole and thiazole compounds showed 5-HT3 antagonist 
properties. HT3 antagonist's agents are highly effective in the control of cancer 
chemotherapy-induced emesis [51]. Derivatives of benzothiazoles, 
mercaptobenzimidazoles are an important class of biologically active compounds that 
can effectively hydrolyze phosphonate diesters and cleave the supercoiled pBR 322 
plasmid DNA. These compounds can selectively interact with a specific nucleotide 
sequence which binds to the minor groove of A-T trace duplex DNA and for such 
studies the benzinudazole unit is a conformationally stable and appropriate ligand 
platform. Peptide ligands significantly alter the biological properties, reactivity or 
substitution inertness. Furthermore, the introduction of chirality (viz. amino acids) 
enhances to a great extent the pharmacological behaviour by adopting specific 
conformation and target selective binding affinity [49, 52, 53]. 
Recently, it has been reported that interaction of L-valine with DNA causes an 
increase in fluorescence emission intensity [53] and produces significant changes in 
CD spectrum. 
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Sokatch et al. reported that L-amino acid induced conformational changes [54] in the 
secondary structure of DNA, binding with the BkdR (a regulator protein) and thus 
increases the susceptibility of BkdR on C-terminal side of DNA binding domain. On 
addition of L-branched amino acids a large change in the CD spectrum is observed. In 
the absence of L-valine, the spectrum revealed single large peak at 283nm with 
shoulders at 273 and 293nm. Whereas in the presence of amino acid, reduction by 
almost half of the peaks at 275nm, 283nm, 293nm and shoulder at 268nm observed, 
although they are similar in shape (Fig. 9a). 
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Fig 9. Effect of L-valine on CD spectrum of BkdR (a) and Emission spectrum of BkdR 
plus L-valine (b) 
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Fluorescence measurements were performed to obtain the information about the 
conformational changes in DNA and in BkdR. The changes in fluorescence emission 
spectrum of BkdR in the presence of L-branched amino acids confirmed that the 
conformational change has occurred in the regulator protein where the excitation and 
emission maxima are 278 and 305nm, respectively. Addition of L-valine with 
increasing amoxmts lead to the increase in the fluorescence emission intensity by 16% 
with no change in the shape of the spectrum (Fig. 9b). 
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Present Work 
The synthesis of chiral compounds is a prominent research area in the field of 
medicinal chemistry. Chiral compounds have a broad range of applications as drugs, 
polymers, probes [55] of biological function and new materials. The optimal 
properties of chiral compounds are only achieved when they are prepared in a pure 
single enantiomeric form. 
Heterocyclic organic compounds bearing benzothiazole, benzimidazole have proved 
their efficiency controlling disease owing to their structural resemblances to the 
purine residue and their potent activity against a number of microorganisms including 
those that lead to AIDS related infections [56]. Tethering these biologically 
significant organic moieties with chiral auxiliaries viz, L-tryptophan and L-valine 
induces chirality in the resulting new compounds creating stereogenic carbon center. 
New chiral compounds 1-3 were synthesized by the reaction of L-protected valine 
with aminobenzothiazole, L-protected valine with mercaptobenzimidazole, 
respectively. The compounds 1-3 were characterized by employing spectroscopic 
techniques IR, ' H and '^C NMR, UV-visible, ESI-MS, CD and analytical methods 
(elemental analysis and polarimetry values). The newly synthesized chiral compounds 
1, 2 and 3 were titrated with CT-DNA to study binding affinity of these compounds 
for molecular DNA at the target site. (Kb values for 1, 2 and 3 are 5.26x10"*, 5.0x10"*, 
and 1.822x105, respectively). The CD spectra clearly show the decrease in the bands 
of CT-DNA upon addition of the compounds indicating electrostatic binding of these 
compounds to CT-DNA. 
13 
Experimental 
CHAPTER II 
EXPERIMENTAL METHODS 
The following techniques were employed: 
1. Characterization techniques 
1.1 Infrared spectroscopy 
1.2 Ultra-violet and visible spectroscopy 
1.3 Nuclear magnetic resonance spectroscopy 
1.4 Mass spectroscopy 
1.5 Polarimetry 
2. DNA binding studies 
2.1 Absorption spectral studies 
2.2 Fluorescence spectral studies 
2.3 Circular dichoric spectral studies 
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1. Characterization techniques 
1.1 Infrared spectroscopy 
The infrared spectroscopy is a useful technique to characterize a compound. It results 
from fransition between vibrational and rotational energy levels. IR region of the 
elecfromagnetic spectrum covers a wide range of wavelength from 200 to 4000 cm '. 
It has been found that in IR absorption, some of the vibrational frequencies are 
associated with specific groups of atoms and remain same irrespective of the 
molecules in which the group is present. These are called characteristic frequencies 
[57] and their constancy results from the constancy of bond force constants from 
molecule to molecule. The important observation that the IR spectrum of a complex 
molecule consists of characteristic group frequencies makes IR spectroscopy, unique 
and powerfial tool in structural analysis. 
1.2 Ultraviolet and visible spectroscopy 
When a molecule absorbs radiation, its energy is increased. This increased energy is 
equal to the energy of the incident photon expressed by the relation 
E = hv 
E = hc/X 
where h is Planck's constant, v is the frequency, X is the wavelength of the radiation 
and c is the velocity of light. Most of the compounds absorb light in the spectral 
region between 200 and 800 nm resulting in the excitation of electrons of the 
15 
molecules from ground state to higher electronic states. There are three types of 
electronic transition which can be considered; 
1. Transitions involving n, a, and n electrons 
2. Transitions involving charge-transfer electrons 
3. Transitions involving d and f electrons 
The atoms, in a molecule can rotate and vibrate with respect to each other. These 
vibrations and rotations also have discrete energy levels, which are considered as 
being packed on top of each electronic level. 
CD 
k _ (D 
C 
UJ 
Rotational 
electronic levels 
Vibrational 
electronic levels 
Fig 10. Energy levels and absorption bands 
Absorption of ultraviolet and visible radiation in organic molecules is restricted to 
certain functional groups (chromophores) that contain valence electrons of low 
excitation energy. The spectra of molecules containing these chromophores are 
complex because of the superposition of rotational and vibrational transitions on the 
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electronic transitions gives a combination of overlapping lines. This appears as a 
continuous absorption band. Possible electronic transitions of n, a, and n electrons are 
shown in Fig.ll. In a —> a , an electron in a bonding a orbital is excited to the 
corresponding antibonding orbital. The energy required is large. For example, the C-H 
bonds in methane can only undergo o -^ G transitions and shows an absorbance 
maximum at 125 nm. Absorption maxima due to a —> a transitions are not seen in 
typical UV-Vis. spectra (200 - 700 nm). 
in 
n-^TT 
-d) 
n—>cr 
TT^TT 
•<e>-
cr—>cr 
Antibonding (j 
Antibonding TT* 
Non-bonding n 
Bonding TT 
Bonding cr 
Fig 11. Electronic energy levels 
whereas, saturated compounds containing atoms with lone pairs (non-bonding 
electrons) are capable of n —> a transitions. These transitions usually need less 
energy than a -> cj transitions. They can be initiated by light whose wavelength is in 
the range 150 - 250 nm. The number of organic functional groups with n -> a* peaks 
in the UV region is small. 
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Most absorption spectroscopy of organic compounds is based on transitions of n or TI 
electrons to the n excited state. This is because the absorption peaks for these 
transitions fall in an experimentally convenient region of the spectrum (200 - 700 
nm). These transitions need an unsaturated group in the molecule to provide the n 
electrons. Molar absorbtivities from n —> n transitions are relatively low, and range 
from 10 tolOO L mof' cm', rt—> TT* transitions normally give molar absorbtivities 
between 1000 and 10,000 L mof' cm'. 
The solvent in which the absorbing species is dissolved also has an effect on the 
spectrum of the species. Peaks resulting from n —> n transitions are shifted to shorter 
wavelengths (blue shift) with increasing solvent polarity. This arises from increased 
solvation of the lone pair, which lowers the energy of the n orbital. Often, the reverse 
(i.e. red shift) is seen for TI —> K transitions. This is caused by attractive polarization 
forces between the solvent and the absorber, which lower the energy levels of both the 
excited and unexcited states. This effect is greater for the excited state, and so the 
energy difference between the excited and unexcited states is slightly reduced -
resulting in a small red shift. This effect also influences n^n* fransitions but is 
overshadowed by the blue shift resulting from solvation of lone pairs [58]. 
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1.3 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The 
NMR spectroscopy is concerned with nuclei having nuclear spin quantum number 
I = 1/2, example of which include ' H , '^C, ^ 'P , " 'Sn and '^F. 
For a nucleus with I = 1/2, there are two values for the nuclear spin angular 
momentum quantum number mi = ±1/2 which are degenerate in the absence of a 
magnetic field. However, in the presence of the magnetic field, this degeneracy is 
destroyed such that the positive value of mi corresponds to the lower energy state and 
negative value to higher energy state separated by AE. 
In an NMR experiment, one applies strong homogeneous magnetic field causing the 
nuclei to presses. Radiation of energy comparable to AE is then imposed with radio 
firequency transmitter equal to precision or Larmor fi-equency and ihe two are ^^ aid to 
be in resonance. The energy can be transferred fi-om the source to the sample. The 
NMR signal is obtained when a nucleus is excited from low energy to high energy 
state. 
1.4 Mass spectroscopy 
At electron beam energy of about 9 to 15 electron volts, depending on the molecule 
involved, a molecular ion is formed by interaction with the beam electrons. 
Recognition of the parent ion (actually a radical ion) is of great importance because it 
gives the molecular weight of the sample [59]. At this point, the molecular weight is 
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an exact numerical molecular weight not the approximation obtained by the all other 
molecular weight procedures. Mass spectra is usually obtained at an electron beam 
energy of 70 electron volts and under these conditions numerous fragment ions 
(including the parent ions) versus their relative concentrations constitutes the mass 
spectrum of the samples. The fragmentations occur on the basis of mass/charge (m/z). 
The largest peak in the spectrum is called base peak and assigned a value of 100%. 
The other peaks are reported as percentage of the base peak. 
1.5 Polarimetry 
Optical isomerism manifests itself by the rotation that certain molecules impart to the 
plane of polarized light when in gaseous, liquid or molten state or in solution (Figure 
15). This rotation is observed and measured by a rather simple instrument, known as 
polarimeter. The specific rotation [ex.] of a dissolved substance is given by the 
expression 
[«.] = 
I x c 
where o( is the observed rotation in degrees 
1 is the path length of the sample in decimeters 
c is the concentration in grams per milliliter 
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The dependence on wavelength and temperature is indicated by subscripts and 
superscripts respectively. Thus MD^^ means the specific rotation at 25 C measured 
at the wavelength of the sodium D line. 
Optical rotation is generally measured using light fi-om a sodium-vapour lamp, which 
gives essentially monochromatic radiation (the yellow sodium D line is a doublet at 
5890 and 5896 A°). A beam of light is polarized by passage through nicol prism (the 
polarizer), 
UupoUnzed 
light 
Tube 
containing 
tampte 
>4'. ' 4 , 
Rotated ~* i-j \ 
ptdari/cd light 1 k 
Figure 12. Rotation of plane of polarized light by optically active compounds 
which consists of two calcite prisms cemented together so that only one of the two 
rays formed by double refi-action is transmitted. The beam of polarized light passes 
through the solution and then through a second nicol prism. When no optically active 
material is placed between the prisms (0° rotation), the prisms are positioned at right 
angles so that no light is transmitted. When an optically active material is placed 
between the prisms, the analyzer must be turned in order to maintain the darkness in 
the field of view. The optical rotation is the angle by which the analyzer is turned in 
order to reach darkness. It is very difficult to determine by eye the setting for 
complete darkness, because positions near the completely dark position are very dark. 
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Therefore, many instruments are constructed such that the field of view is divided into 
two equal parts, and the analyzer is adjusted so as to equalize the light intensity in 
each half of the field. 
2. DNA binding studies 
CT DNA was procured from Sigma Chemical Company and tris base was obtained 
from E. Merck. All the experiments involving interaction of the complexes with CT 
DNA were conducted in buffer containing tris (0.01 M) adjusted to pH 7.2 with 
hydrochloric acid. The CT DNA was dissolved in tris-HCl buffer and was dialyzed 
against the same buffer overnight. Solutions of CT DNA gave ratios of UV 
absorbance at 260 and 280 nm above 1.8, indicating that the DNA was sufficiently 
free of protein [60]. DNA concentration per nucleotide was determined by absorption 
spectroscopy using the molar absorption coefficient 6600 dm^ mof' cm'' at 260 nm 
[61]. The stock solution was stored at 4°C. 
2.1 Absorption spectral studies 
In a closed constant volume system, the rate of a chemical reaction is defined as the 
rate of change of the concentration of any of the reactants and products with time. The 
concentration can be expressed in any units of quantity per unit volume e.g. .moles 
per liter, moles per cubic centimeter. The rate will be defined as positive quantity 
regardless of the component whose concentration change is measured. 
79 
The rate of a chemical reaction is not measured directly instead the concentration of 
one of the reactants or products is determined as a function of time. A common 
procedure for determining the reaction order is to compare the experimental results 
with integrated rate equations for reactions of different orders. For a first order rate 
equation, integrating by separate variables using integration limits such that at t = 0, c 
= Co and at t = t, c = c. [62]. 
-dc/dt = kc 
or In (co/c) = kt 
The intrinsic binding constant Kb of the complex to CT DNA was determined from 
Eqn. (1), through a plot of [DNA]/ Sa-Sf vs. [DNA], where [DNA] represents the 
concentration of DNA, and £a, 8f, and e\, the apparent extinction coefficient (Aobs 
/[M]), the extinction coefficient for fi-ee metal complex (M), and the extinction 
coefficient for the firee metal complex (M) in the fully bound form, respectively. 
In plots of [DNA]/8a-£f vs. [DNA], Kb is given by the ratio of slope to intercept [63]. 
These absorption spectral studies were performed on a UV-1700 Pharmaspec. 
Shimadzu Spectrometer. 
[DNA] = [DNA] ^ _ J (1) 
Ea-Ef Sb-8f Kb(8b-ef) 
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2.2 Fluorescence spectral studies 
When molecules that have absorbed light are in a higher electronic state, they must 
lose their excess energy to return back to the ground state. If the excited molecule 
returns to the ground state by emitting light, it exhibits fluorescence and spectrum 
thus obtained is called emission spectrum. This phenomenon is generally seen at 
moderate temperature in liquid solution. The emission spectrum is obtained by setting 
the excitation monochromator at the maximum excitation wavelength and scanning 
with emission monochromator. Often an excitation spectrum is first made in order to 
confirm the identity of the substance and to select the optimum excitation wavelength. 
Further experiments were carried out to gain support for the mode of binding of 
compounds with CT DNA. The interaction procedures of the compounds were carried 
out with CT DNA in pH 7.4 with increase in concentrations of DNA. The 
concentrations of CT DNA per nucleotide phosphate were calculated according to the 
absorbance at 260 nm by using molar absorption coefficient 6600 dm^ mol ' cm'. 
When fluorescence emission is enhanced, the concentration of the bound probe can be 
calculated by the following equation: 
CB=CT(F /FO-P) (1 -P ) 
Where, CB, CT are the concentration of the bound probe and the total probe added, 
respectively. F is the observed fluorescence emission intensity under a particular set 
of DNA and drug concentrations, Fo is the emission of the same drug concentration in 
the absence of DNA, and P is the ratio of the fluorescence of the completely bound 
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probe to that of the free probe. The value P was obtained as the intercept by 
extrapolating from a plot of F/F© vs. 1/ DNA. Thus, the intrinsic binding constant K 
can be calculated on the basis of the recorded fluorescence titration data using the 
Scatchard's equation. 
r/c- K (n-r) (2) 
Where, K is the intrinsic binding constant, n is the number of binding sites, r is the 
ratio of CB and DNA concentration and c is the free probe concentration. The amount 
of bound probe CB at any concentration is equal to Cj - Cp. Emission intensity 
measurements were carried out using Hitachi F-2500 spectrofluorometer at room 
temperature [64, 651. \\av^» ^"^'^ C A 
\^i --'^cc. Nt ^ _. ) ^ ' 
2.3 Circular dichoric studies ^ / i r ^ s . . - ^ s _ / - " ' ^ ' 
Circularly polarized light represents a wave in which the electrical component spirals 
around the direction of propagation of the ray, either clockwise or counterclockwise. 
Within the absorption band, the molar absorptivity for right and left handed circularly 
polarized light is different, that is (Cd-ei) ^ 0. This effect changes linearly polarized 
light into elliptically polarized light and is known as circular dichroism. 
When a substance near an absorption band absorbs left circularly polarized light, the 1 
component, more sfrongly than the right circularly polarized light, the d component, 
i.e. 8i > 8dthen the amplitude of d component will be greater than the 1 fiirthermore, if 
Ed > El then the d component will be retarded more than the 1 component (Figure 16). 
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The ellipticity, that is the angle whose tangent is ratio of minor axis of the elhpse OB 
to the major axis OA, is denoted by 6- The molecular ellipticity [&] can be shown by 
the relationship [66]. 
[9] - 3305 (e, - Ed) 
N . J , ^ « H 
d component 
/ component 
Plane of , \ 
inddeitt beam -<n \ 
« \ 
\ \ 
Figure 13. Elliptically polarized light produced whenV^^^'^li and £i>kd 
Circular dichroism graphs are plots of [Q] against wavelength. Circular dichoric 
spectra were obtained on JASCO J-715/J-710 CD spectropolarimeter at 25° C. 
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Experimental 
Materials and Methods 
All the reagents were of best commercial grade and used without further purification. 
L-valine and L-tryptophan (loba chemie), 2-aminobenzothiazole (Fluka), 2-
mercaptobenzimidazole (Aldrich) were used as received. Pthallic anhydride and 
triethylamine, CT DNA was purchased from E.Merck, Sigma Chemical Co., 
respectively. 
Carbon, hydrogen and nitrogen contents were determined on Carlo Erba 1108 
analyzer. Fourier-transform IR (FTIR) spectra were recorded on an Interspec. 2020 
FTIR Specrometer in KBr pellets. UV-visible spectra were recorded on a UV-1700 
Pharmaspec. Shimadzu Spectrometer in methanol and the data were recorded as 
'^ max/nm. The ' H and '^C NMR spectra were obtained on a Brukner DRX-300 
Spectrometer at room temperature. Optical rotations of chiral compounds were 
determined on a Polarimeter Rudolph Autopol III at 25°C using the sodium D line in 
methanol. ESI-MS Spectra were recorded on Micromass Quattro 11 triple qudrupole 
mass-spectrometer. Fluorescence titration measurements were carried out using 
Hitachi F-2500 Spectofluorometer at room temperature. CD studies were done on 
Jasco-J-715-CD Spectropolarimeter at room temperature. 
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Syntheses 
Syntheses of N-phthaloyl-L-valine 
N-phthaloyl-L-valine (NH2 group of valine protected) was synthesized according to 
the procedure reported eariier [67] and has been described below. 
A solution of L-valine (3g, 0.0256mol) and triethylamine (2.6g) in 40ml of water was 
added with stirring to a solution of pthallic anhydride (3.8g) in 130ml of dioxane. 
During the addition a small amount of precipitate was formed which dissolved again 
after 5 min of vigorous stirring. The resultant homogenous solution was then stirred at 
room temperature for another 45 min. during which time an additional 2.6g of 
triethylamine was gradually added. Another 130ml of dioxane was then added to the 
solution and the solution was then subjected to slow distillation for a period of 2h. 
Diiring this time a total of 265ml of liquid was distilled and the temperature of the 
vapour rose slowly until finally the boiling point of pure dioxane was reached. The 
residual solvent was then evaporated in vacuo at room temperature. The resultant 
glassy residue treated with 10ml of pure cone, hydrochloric acid until complete 
crystallization set in. The precipitate was then filtered, washed with a little cold water, 
and air dried. Yield: 5.7g (90%). m.p: 116-117°C. [C\]D^^: - 69.4 
Synthesis of C12H17N3O3S (1) 
To the solution of N-phthaloyl-L-valine (Ig, 0.004mol) in 30ml of methanol was 
added to a methanolic solution of 2- aminobenzothiazole (0.625g, 0.004mol) in 1:1 
molar ratio. The mixture refluxed for 36 h. Colourless solution turned to light yellow. 
28 
On concentrating the solution mixture, off white solid product appears, which was 
filtered, washed with diethyl ether and dried in vacuo. Yeild: 66%. m.p; 150-168°C: 
[O(]D^ ; -10: Anal.Calcd for C,2H,7N303S: C, 63.31; H, 4.5; N, 11.07. Found: C, 
63.20; H, 4.2;N, 11.00. Selected IR data in KBr (V/cm"'): 3397^ (N-H); 1661(Amide 
I); 1551 (Amide II); 424 (Ar out of plane C=C bending); 1288, 1119 (In plane C-H 
bending); 2776 (Ar C-H). ' H N M R (400MHZ, D M S O ) ; d (ppm): 6.9 (N-H); 7.5-7.7 
(Ar-H); 3.6 (C-H); 2.5 (CH3). '^C NMR (DMSO-de, 400MHz); 152.8 (NH-C=0); 
166.9 (N-C=0); 121-133 (ArC); 39.5 (CH2). ESI (m/z^): 235 [C4H,3N20S]^ 
Synthesis of C12H17N3O3S (2) 
To the solution of N-phthaloyl-L-valine (Ig, 0.004mol) in 30ml of methanol was 
added to amethanolic solution of 2-mercaptobenzimidazole (0.625g, 0.004mol) in 1:1 
molar ratio. The mixture was refluxed for 36 h. The solvent was then evaporated 
under reduced pressure to give the final product. This was filtered, washed with 
diethyl ether and dried in vacuo. Yield: 62%. m.p:280°C (Decompose) M D ^ ^ -24. 
Anal.Calcd for C12H17N3O3S; C, 63.31; H, 4.5; N, 11.07. Found: C, 63.00; H, 4.50;N, 
11.49. Selected IR data in KBr (V/cm"i): 3156 (N-H); 742 (C-S); 416 (Ar out of plane 
C=C bending); 1258, 1177 (Li plane C-H bending); 2984 (Ar C-H). ' H NMR 
(400MHz, DMSO); d (ppm): 12.2 (N-H); 7.06-7.71 (Ar-H); 3.17 (CH); 2.5 (CH3). '^ C 
NMR (DMSO-d6, 400MHz); d (ppm): 167.6 (N-C=0); 13-121 (Ar); 39.4 (CH2). ESI 
(m/z^): 365 [CiiHi4N303S]^ 
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Synthesis of C18H16N4OS (3) 
To a solution of L-tryptophan (0.0225g, O.OOlmol) in 30 ml of methanol was added to 
amethanolic solution of 2-mercaptobenzimidazole (0.1877g, O.OOlmol) in 1:1 molar 
ratio. The reaction mixture was refluxed for 72 h. On concentrating the reaction 
mixture, maroon solid product settles which was suction filtered and dried in vacuo. 
Yield: 58 %. m.p: 290-295°C. [O(]D": -28. Anal.Cald. for C18H16N4OS: C, 64.31; H, 
4.76; N, 16.6. Found: C, 64.76: H, 4.70: N, 16.50. Selected IR data in KBr (v/cm'): 
1669 (antisym C-0); 1451 (sym C-0); 1236 (imidazole N-H); 3402 (indole N-H); 748 
(C-S). ' H N M R (400MHz, DMSO); d (ppm): 10.99 (N-H); 7.1 (CH=C); 7.01-7.55 
(Ar-H); 3.40 (CH); 2.97(CH2). '^C NMR (DMSO-de, 400MHz); d (ppm): 170 (C=0); 
57 (CH); 39.50 (CH2); 120-124 (Ar); 116 (N-CH). ESI (m/z^): 205 [CgHgNjOS]^ 
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Synthetic Scheme 
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Results and Discussion 
CHAPTER III 
Results and Discussion 
The compounds 1-3 were synthesized by employing de novo synthetic strategy, by 
condensation reactions of N-protected (-valine with pharmacologically active 2-
aminobenzothiazole 1, 2-mercaptobenzimidazole 2 and L-tryptophan with 2-
mercaptobenzimidazole 3, respectively. 
All the reactions were monitored by TLC and compounds synthesized were TLC 
pure. The compounds are stable towards air and moisture and soluble in MeOH, 
EtOH, DMSO, DMF and THF. The presence of chiral auxiliary L-valine and L-
tryptophan induced chirality in these compounds which is given by optical rotation 
[G(]o25 values of -10, -24, -28, respectively. The structure of the compounds was 
proposed on the basis of elemental analysis and spectroscopic data IR, 'H and I3C 
NMR and ESI-MS spectral studies. 3-D molecular structure of compounds 1-3 was 
done on CS Chern. Ultra 3D Pro 5.0 program (Fig. 14). 
IR Spectroscopy 
The important i.r bands of pure 2-aminobenzothiazole, 2-mercaptobenzimidazole, N-
phthaloyl-L-valine were compared to study the mode of formation of the compounds. 
The i.r spectra of pure 2-aminobenzothiazole and 2-mercaptobenzimidazole show 
characteristic bands at 3397 em-I and 2582 cm-I due to -NH2 and -SH stretching 
vibrations, respectively [51,68]. However, the characteristic i.r band ofN-pthaloyl L-
valine appears at 1640 em-I (symm COO); 13lOem-1 (antisymm. COO) [49]. The 
emergence of the new bands in 1 at 1661 em-I and 1551 cm-I corresponds to amide I 
and amide II region [69, 70] and the disappearance of band at 3397 cm- l is related to 
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N-H stretching which further confirms the formation of the compound. Similarly, the 
disappearance of the vS-H at 2582 cm"' in 2-mercatobenzimidazole reveals the 
formation of compound 2. However, the N-H band at 3156 cm' of benzimidazole 
ring [71] remains unaltered in this compound. 
In compound 3, the characteristic bands at 1669 and 1451 cm' 
observed in the fi-ee amino acid assigned to antisymmetric and symmetric 0-C=0 
stretching modes were shifted to lower frequencies, suggesting the terminal 
coordination mode of carboxylate group of L-tryptophan [49]. The IR spectrum of the 
compound exhibits a band at 3402 cm' which corresponds to indole v(NH). The 
presence of a sharp band around 748 cm"' show characteristic v(C-S) vibrations [53], 
which remain unaltered indicative of deprotonation of mercapto group (Fig. 15). 
Medium intensity bands in the region 1236 cm"' due to imidazole -NH were also 
observed. 
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Fig 15. Comparison of the IR spectra of 3 with 2-mercaptohenzimidazole 
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NMR Spectroscopy 
The formation of the compounds 1, 2 and 3 was ascertained by ' H and '^C NMR 
spectroscopy. The ' H NMR spectrum of the compound 1 displays signals at 3.6 and 
2.5 ppm corresponding to CH and CH3 protons of amino acid moiety. The 
characteristic aromatic protons of benzothiazole group were observed in the range 
7.06-7.71 ppm. The spectrum also exhibits a singlet at 7.01 ppm owing to the NH 
proton of the amide linkage [70, 72]. Similarly, compound 2 revealed CH, CH3 and 
aromatic protons at 3.17, 2.5 and 7.06-7.71 ppm, respectively. The presence of signal 
at 12.2 ppm due to the imine proton of the 2-mercaptobenzimidazole authenticates the 
formation of the compound 2 via deprotonation of the SH group. This is also 
authenticated by the absence of the signal at 14 ppm [73]. 
' H NMR spectum of the compound 3 exhibited prominent signals at 7.01-7.55 ppm 
and 10.99 ppm characteristic of aromatic and mdole NH proton of the tryptophan 
moiety [74]. Other resonances at 3.40, 2.97 and 7.1 ppm corresf>onds to asymmetric 
CH, CH2 and CH=C groups, respectively. However, the most remarkable feature is 
the absence of characteristic COOH resonance at 12.00 ppm, suggestive of 
deprotonation of the OH proton from he carboxylic group of L-tryptophan and 
subsequent S-C=0 formation with the SH group of 2-mercaptobenzimidazole. 
Additionally the imine proton of the imidazole ring occurs at 6.95 ppm [49]. 
The '^C NMR data of the compounds 1, 2 and 3 is in good agreement with the ' H 
NMR spectra of the compounds 1 and 2 displayed CONH, C=0, C-Ax and CH3 group 
protons in the region 152.8, 167.6, 121-133 and 39.9 ppm, respectively [44,75]. 
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Similarly, compound 3 resonances at 170, 57, 39.5, 120-124 and 116 ppm were 
ascribed to C=0, CH, CH2, C-Ar and N-CH groups of the tryptophan residue [49]. 
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Fig 16. (a) 'HNMR of compound 1(b) Amide resonance at 7.01 ppm 
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Electronic spectrum 
UV-visible spectra of compounds 1, 2 and 3 recorded in methanol at room 
temperature. Compound 1 exhibits two bands. A broad absorption band maximum 
centered at 261 nm and second band with shoulders at 221, 211 and 224 nm. 
Compound 2 displayed three well defined bands at 305, 245 and 218 nm. The intense 
band observed at 305 imi arises fi-om intraligandTt- -n* transitions. Compuond 3 shows 
less intense absorption bands as compared to 1 and 2. Broad and smooth band at 288 
nm is observed. In addition, other bands at 223, 211 nm are also observed which are 
attributed totr-TT* transitions of aromatic chromophore. The longer wavelength 
bands in these compounds are due to n- -jf* transitions of the heteroaromatic ring 
system [76, 77]. 
Interaction studies of compounds with CT-DNA 
Steady - State Emission Titration 
The binding of the compounds 1 and 2 to DNA has been studied by emission titration 
at 342 and 458 nm, respectively. Compounds 1 and 2 emit luminescence in tris buffer 
upon excitation at 220 nm. Fixed amoimts of 1 (0.2x10"^ M) and 2 (0.4x10'^ M) were 
titrated with increasing amounts of DNA (0.06-0.4x10"^ M). The results of emission 
titrations are depicted in Fig 17. Upon the addition of DNA, an appreciable increase in 
emission intensity of 1 and 2 is observed. The stronger emission enhancement is 
indicative of the binding of the compounds 1 and 2 to the hydrophobic pocket of 
DNA [78]. The hydrophobic environment inside the DNA helix reduces tiie collision 
between the solvent molecules and the probe molecules, restricting the mobility of the 
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later at the binding site and consequently prevents the fluorescence quenching [79]. 
The DNA binding parameters of 1 and 2 were determined quantitatively from the 
binding data obtained from the emission specfra, using Scatchard equation. 
r/c= K(n-r) 
Where, r is the amount of boimd probe to DNA, K is the intrinsic binding constant 
and n is number of binding sites. Fluorescence scatchard plots for the binding of the 
compound 1 and 2 are given in Fig. 18. From the plots the DNA binding constants of 
1 and 2 were estimated as 6.0x10^ and 2.3x10^ M"', respectively. The binding sites n, 
was found to be 0.03 for 1 and 0.0029 for 2. 
I I I—r—p-'—' ! 1 I • ' ' I r •" 
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Fig 17. Emission Spectra of compounds 1 (A) and 2 (B) in Tris-HCl buffer in the 
presence of increasing concentration ofCT-DNA. 
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Absorption Titration 
The UV-absorption spectra of compounds 1, 2 and 3 exhibits strong absorption bands 
at 261 nm, 245 nm and 211 nm, respectively are depicted in Figure 19, which were 
assigned tOTf-TT* transitions of aromatic chromophore. The interaction of these 
compovinds with CT-DNA was investigated by titration of fixed amounts of the 
compounds (0.06x10"^ M). On increasing the concentration of CT-DNA from 
0.06x10"* to 0.33x10"* M, an increase in the absorption intensity viz. hyperchromism 
is observed with increase in the value of absorbance, which indicates that the 
compound interacts with DNA. The hyperchromic effect arises from the damage of 
double helix structure of CT-DNA [80]. Therefore, the observed hyperchromicities on 
addition of 1, 2 and 3 to CT-DNA reflects binding of compounds to the DNA base 
moieties through elecfrostatic interaction. Although the hydrogen bonding interactions 
can not be neglected, as DNA possesses several hydrogen bonding sites which are 
accessible both in the minor and major grooves [81, 82]. 
In order to determine the binding sfrength of compoimds 1, 2 and 3 with CT-DNA, 
the intrinsic binding constants Kb of the compounds was calculated with the equation 
1, by monitoring the change in the absorbance with increasing concentration of DNA 
(Fig. 20). The value of intrinsic binding constant Kb is given by slope to the intercept. 
The binding constant obtained for 1, 2 and 3 are 5.26xl0^ S.OxlO'* and 1.822xl0^ 
respectively. The value of Kb suggests strong binding affinity to calf thymus DNA. 
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Fig 19. Absorption Spectra in Tris-HCl buffer of (a) compound 1, (b) compound 2, (c) 
compound 3 upon addition ofCT-DNA. 
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Circular dichoric studies 
Circular dichoric studies are useful in diagnosing morphological changes in DNA 
during compound-DNA interaction. The CD spectrum in the UV region of the CT-
DNA exhibits a positive band at 273nm due to base stacking and a negative band at 
245nm due to helicity of right handed B form of DNA [83]. Simple groove binding 
and electrostatic interactions of small molecules with DNA show little or no 
perturbations on the two bands [84, 85]. 
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Fig 21. CD Spectra of (a) CT-DNA alone. (b)CT-DNA in presence of compound 3. (c) 
CT-DNA in presence of compound 1, (d) CT-DNA in presence of compound 2. 
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Addition of compounds 1, 2 and 3 shows significant changes in the CD spectrum of 
CT-DNA (shown in Fig. 21). The spectrum of DNA on addition compound 1, shows 
decreEise in the intensities of both the negative and positive bands without any shift in 
the band position. 2 also display similar decrease in intensities of the two bands, but 
the position of the positive band shifts from 273 to 278nm. In the presence of 
compound 3, the positive and negative ellipticity bands decreases. This decrease in 
intensity is less compared to 1 and 2. No shift in band position is observed. These 
results support that compound—CT-DNA interaction takes place and the binding of 
the small molecules with DNA induces conformational changes within the DNA 
molecule. 
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Conclusion 
In this work, an attempt has been made to design and synthesize some bioactive drug 
scaffolds, which can be utiUzed as chiral ampHfiers in the formation of cancer 
chemotherapeutic asymmetric agents. In particular, the interaction of the compounds 
1-3 with DNA ascertains the potential to act as DNA inhibitors as DNA is the primary 
target for most of anticancer drugs. The fluorescence spectra of the compounds 
demonstrate that they are superior sensors to DNA helix and have access to 
hydrophobic exterior surface of DNA which is clearly observed by the enhancement 
of the emission intensity in the scatchard plots. This is indeed an interesting property 
owing to the presence of biologically significant benzimidazole moieties. 
Benzimidazole derivatives are considered important class of therapeutic — drugs; 
constituents of vitamin B12 bearing resemblance to purine nucleobases which are 
capable of sequence selective DNA recognition. Incorporating benzimidazole 
compounds with other chelating ligands or amino acids in presence of metal ions 
(biocompatible) further can offer, new class of metal-based combinatorial anticancer 
agents. 
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